ImmunoGen Stock News

Vertex Pharmaceuticals recently completed regulatory requests for its blood disorder candidate, exa-cel. Exa-cel has what it takes to become a blockbuster over time.

ImmunoGen, Inc. (NASDAQ:IMGN ) Q4 2022 Earnings Conference Call March 1, 2023 8:00 AM ET Company Participants Anabel Chan - Head, IR Mark Enyedy - President and CEO Anna Berkenblit - Chief Medical Off

ImmunoGen (IMGN) delivered earnings and revenue surprises of 20.69% and 132.98%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ImmunoGen (IMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 65.09% and 3.82%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock

IMGN received its first approval after 40 long years. However, ocular toxicity and confusing PFS are some of the problems here.

WALTHAM, Mass.--( BUSINESS WIRE )--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following pr

Cigna's (CI) fourth-quarter results are likely to reflect increased Evernorth and Cigna Healthcare profits.

Humana's (HUM) fourth-quarter results are likely to reflect surging Healthcare Services profits on strong pharmacy business.

HCA Healthcare's (HCA) fourth-quarter results are likely to reflect increased equivalent admissions and outpatient surgery cases.

Analysts have provided the following ratings for Immunogen (NASDAQ:IMGN) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 2 1 0 0 Last

Elevance Health's (ELV) fourth-quarter results are likely to reflect higher premiums, Commercial & Specialty Business' sales and total expenses.

Aurinia (AUPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the roa

Analysts have provided the following ratings for Immunogen (NASDAQ:IMGN) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 2 0 0 0 Last

U.S. stocks traded lower, with the Dow Jones dropping over 200 points on Friday. Here are some big stocks recording losses in today’s session. Futu Holdings Limited (NASDAQ: FUTU) shares dipped 24.